Search Results
You are looking at 1 - 10 of 26 items for
- Author: L. H. Rees x
- Refine by access: All content x
Search for other papers by R. Buzzetti in
Google Scholar
PubMed
Search for other papers by L. McLoughlin in
Google Scholar
PubMed
Search for other papers by D. Scavo in
Google Scholar
PubMed
Search for other papers by L. H. Rees in
Google Scholar
PubMed
Introduction
Many publications in recent years have greatly enhanced our understanding of the interrelationship between the immune system and the hypothalamo-pituitary-adrenal axis (HPA). Previously, the primary interaction between the two systems was ascribed to the effects of glucocorticoids on the immune response (Fauci, 1979). Recent studies, however, have shown the presence of additional interactions between the immune system and the HPA axis, which have led some authors to postulate the existence of reciprocal circuits as summarized in Fig. 1. At this time several of the links are hypothetical, as many reports are contradictory, and await further research for confirmation. This review is an attempt to clarify this complex area and is a critical assessment of published data which has enabled such a diagram to be constructed.
For Fig.1 to be an accurate reflection of the physiological state, three major criteria have to be proven. These are (1) the presence of both
Search for other papers by S. Medbak in
Google Scholar
PubMed
Search for other papers by D. F. J. Mason in
Google Scholar
PubMed
Search for other papers by L. H. Rees in
Google Scholar
PubMed
ABSTRACT
The involvement of endogenous opioid peptides in the stress response was investigated by measuring plasma concentrations of Met-enkephalin-like immunoreactivity (MLI), adrenaline and noradrenaline during insulin-induced hypoglycaemia in conscious greyhounds. Moreover, the molecular forms of circulating MLI were characterized using gel filtration chromatography.
In the first group of animals, i.v. administration of insulin (0·3 units/kg) provoked marked hypoglycaemia (blood glucose concentrations fell from 4·4 ± 0·1 to 1·5 ±0·2 mmol/l; mean ± s.e.m.) which was associated with significant (P< 0·001) rises in plasma MLI concentrations from a basal concentration of 45 ± 8 to a peak of 189 ±39 ng/l.
A within-subject study comparing five different insulin doses ranging from 0·004 to 0·3 units/kg showed dose-related effects on blood glucose with nadir concentrations of 4·1 ± 0·6 mmol/l (after the smallest dose of insulin) and 0·8 ± 0·1 mmol/l (after the largest dose of insulin). This was associated with dose-related rises in plasma MLI with peak concentrations of 56±17 and 558 ± 35 ng/l, plasma adrenaline with peak concentrations of 0·45± 0·06 and 15·76±1·33 nmol/l and plasma noradrenaline with peak concentrations of 0·49 ± 0·07 and 2·27 ± 0·45 nmol/l following the smallest and largest doses of insulin respectively. These results are the first demonstration of raised plasma MLI concentrations following hypoglycaemia. Moreover, they show that the hormonal responses vary with the degree of hypoglycaemia achieved. Together with reports by other investigators these findings might suggest opioid modulation of the responses of the sympathoadrenal system to hypoglycaemia. These responses were, however, not modified by the opioid antagonist naloxone.
Gel filtration chromatography of neat (unextracted) plasma revealed the predominance of large molecular weight enkephalin-containing peptides, with approximate molecular weights of 18 000 and 8000, both basally and following stimulation by hypoglycaemia.
J. Endocr. (1987) 114,81–87
Search for other papers by T. A. Howlett in
Google Scholar
PubMed
Search for other papers by G. M. Besser in
Google Scholar
PubMed
Search for other papers by L. H. Rees in
Google Scholar
PubMed
ABSTRACT
The prodynorphin-derived opioids, dynorphin (DYN) and α-neoendorphin (αNE) were studied in 24 human phaeochromocytomas and related tumours. Nineteen tumours, extracted in HCl (0·1 mol/l), contained concentrations of immunoreactive DYN (ir-DYN) ranging from < 0·5 to 794 pmol/g wet weight. None of the extracts in HCl contained ir-αNE (all < 2·4 pmol/g). Sephadex G-50 gel filtration chromatography of ir-DYN in HCl (0·1 mol/l) extracts of six tumours revealed three small peaks of ir-DYN of higher molecular size (approximately 12 000, 6000 and 3000 daltons), a minor peak of ir-DYN eluting just after DYN(1–17), and a broad major peak, consisting of at least three components, which was significantly retarded and eluted after the salt volume of the column. High-pressure liquid chromatography (HPLC) of these extracts revealed multiple peaks of ir-DYN, most of which did not coelute with any synthetic DYN peptides. On both gel filtration chromatography and HPLC, one of the minor peaks coeluted with DYN(1–32). None of the peaks of ir-DYN coeluted with DYN(1–17) which had been acetylated using acetic anhydride.
Extracts of the same tumours in acetic acid (0·1 mol/l) yielded similar values for ir-DYN content, but parallelism in the assay was improved. Sephadex G-50 chromatography revealed a different pattern of ir-DYN with a major peak coeluting with DYN(1–17) and, in two tumours, a minor peak coeluting with DYN(1–8). Studies with HPLC revealed, however, that substantial degradation of synthetic DYN occurred during extraction in acetic acid (0·1 mol/l) in spite of the precautions taken.
Phaeochromocytomas frequently contain ir-DYN in concentrations which may approach that of the mammalian pituitary. These tumours did not, however, contain ir-αNE and, with the possible exception of a small amount of DYN(1–32), the ir-DYN present did not correspond with any known sequences. Thus, whilst prodynorphin is expressed in phaeochromocytomas, it does not seem to be processed to the usual end-products, and post-translational modifications therefore seem likely. Enzymatic degradation of DYN may occur during extraction in acetic acid (0·1 mol/l), and this medium should, therefore, be avoided in studies of such labile peptides.
J. Endocr. (1988) 117, 123–132
Search for other papers by S. Medbak in
Google Scholar
PubMed
Search for other papers by D. F. J. Mason in
Google Scholar
PubMed
Search for other papers by L. H. Rees in
Google Scholar
PubMed
ABSTRACT
The mechanisms involved in the release of Metenkephalin-like immunoreactivity (MLI) into the circulation following oral administration of ethanol and chlorpropamide were investigated in dogs. The origin of plasma MLI and the sites where it may be metabolized were also studied. Moreover, the molecular nature of circulating MLI was characterized.
In conscious animals oral administration of ethanol (0·15 ml/kg) led to a significant (P<0·01) rise in plasma MLI concentrations in chlorpropamidepretreated animals from a basal level of 43 ± 6 (mean ± s.e.m.) to a peak of 66 ± 8 ng/l. Similar rises in MLI concentrations were observed following administration of ethanol with disulfiram and ethanol with chlorpropamide and captopril. In contrast, the administration of ethanol alone or ethanol with 4-methylpyrazole resulted in a decrease in plasma MLI concentrations.
Comparisons of two different doses of i.v. acetaldehyde, the first metabolite of ethanol, showed that plasma MLI concentrations rose significantly (P<0·05) only after the larger dose (8 mg/kg), rising from 45±7 to 81 ± 18 ng/l. These results suggest that acetaldehyde is the active component in the chlorpropamide+ ethanol-induced MLI secretion.
Plasma MLI was also measured following acetaldehyde infusion in adrenalectomized dogs with and without hexamethonium treatment. Acute bilateral adrenalectomy resulted in a decrease (P<0·05) in plasma MLI concentrations, but the levels remained detectable. Moreover, subsequent acetaldehyde infusion led to rises in plasma MLI similar to those observed in animals with intact adrenals. These MLI responses were not altered by the concurrent i.v. administration of hexamethonium. Gel filtration chromatography revealed that Met-enkephalin exists in the circulation predominantly in larger molecular forms with approximate sizes of 18 000 and 8000 Da in the basal state, after stimulation and following adrenalectomy.
Journal of Endocrinology (1989) 120, 473–480
Search for other papers by A. C. Hale in
Google Scholar
PubMed
Search for other papers by G. M. Besser in
Google Scholar
PubMed
Search for other papers by L. H. Rees in
Google Scholar
PubMed
ABSTRACT
The molecular forms of pro-opiomelanocortin in plasma of normal subjects and plasma and tissue extracts from patients with disorders of the hypothalamic-pituitary-adrenal axis have been characterized using gel filtration chromatography under acid dissociating conditions, and the molecular forms further investigated by high pressure liquid chromatography and affinity chromatography. A large molecular weight MSH/ACTH fragment was observed in all plasma samples chromatographed, although the proportions of this fragment were significantly greater in patients with the ectopic ACTH syndrome. A similar profile was observed in tumour extracts: a greater proportion of large molecular weight precursors was observed. Immunoreactive-γ-MSH in extracts of ectopic tumours displayed marked and variable heterogeneity, and affinity chromatography with Concanavalin A-Sepharose indicated that this was due to differential glycosylation. High pressure liquid chromatography of a peak of amino terminal pro-opiomelanocortin (N-POC(1–76)) and 22 000 mol. wt MSH/ACTH indicated two peaks in each peptide, again possibly due to differential glycosylation. A possible neurointermediate lobe origin of atypical invasive pituitary tumours is discussed.
J. Endocr. (1986) 108, 49–56
Search for other papers by K. D. R. SETCHELL in
Google Scholar
PubMed
Search for other papers by LESLEY H REES in
Google Scholar
PubMed
Search for other papers by R. L. HIMSWORTH in
Google Scholar
PubMed
SUMMARY
The half-life of plasma cortisol in the rhesus monkey (M. mulatta), determined by two methods, was about 130 min and longer than that in man; it was unaffected by administration of dexamethasone. Dexamethasone (5 mg, i.v.) immediately inhibited the secretion of ACTH from the monkey pituitary. The plasma half-life of NH2-terminal immunoreactive ACTH was found to be about 55 min which was much longer than the biological half-life. The adrenal synthesis of cortisol was inhibited by metyrapone which caused a prompt increase in the plasma concentration of ACTH and 11-deoxycortisol. The hypothalamicpituitary-adrenal system of the rhesus monkey sedated with phencyclidine hydrochloride responded rapidly to alteration in the level of steroids in the circulation.
Search for other papers by D. S. Jessop in
Google Scholar
PubMed
Search for other papers by R. L. Patience in
Google Scholar
PubMed
Search for other papers by D. Cunnah in
Google Scholar
PubMed
Search for other papers by L. H. Rees in
Google Scholar
PubMed
ABSTRACT
Degradation of tracer during a radioimmunoassay (RIA) can result in false-positive concentrations of immunoreactivity being reported in a biological sample. A technique has been developed using reversed-phase high-performance liquid chromatography (HPLC) to detect proteolytic degradation of corticotrophin-releasing factor-41 (CRF-41) during incubation with tissue extracts under RIA conditions. Human pancreatic tissue was extracted in HCl or urea and incubated with 125I-labelled CRF-41 at neutral pH for 18 h. When samples were analysed by HPLC and fractions counted for radioactivity, tracer was extensively degraded. Heating extracts at 85 °C or adding lima bean trypsin inhibitor to the medium prevented degradation. Pancreatic tissue extracted in HCl was analysed by gel filtration and HPLC, and fractions were subjected to RIA for CRF-41. A peak of immunoreactivity was detected by both chromatographic methods. However, when this material was incubated with tracer and analysed by HPLC, the tracer was degraded, indicating that proteolytic activity remained after acid extraction and two forms of chromatography.
J. Endocr. (1987) 114, 147–151
Search for other papers by L. McLoughlin in
Google Scholar
PubMed
Search for other papers by S. F. Evans in
Google Scholar
PubMed
Search for other papers by J. D. Watson in
Google Scholar
PubMed
Search for other papers by C. J. Hinds in
Google Scholar
PubMed
Search for other papers by L. H. Rees in
Google Scholar
PubMed
ABSTRACT
The nature of circulating pro-opiomelanocortin (POMC)-related peptides was investigated in patients with a diagnosis of septic shock. Also, changes following administration of methylprednisolone were monitored using established chromatographic techniques and three radioimmunoassays directed towards the N-terminal, mid-portion and C-terminal regions of the precursor.
Adrenocorticotrophin and β-endorphin-like peptides were identified in the circulation. By 60 min after a pharmacological dose of methylprednisolone (30 mg/kg) concentrations of these peptides were reduced and continued to fall up to 180 min. β-Lipotrophin and N-terminal POMC(1–76) were also detected by the β-endorphin and γ3-MSH assays respectively. The concentrations of these peptides were noticeably reduced only after 180 min.
The 31 000 Da MSH/ACTH/β-endorphin (POMC) and the 22 000 Da MSH/ACTH precursors were also present in the circulation in septic shock and their concentrations increased following steroid treatment.
J. Endocr. (1988) 119, 159–165
Search for other papers by J. F. Ackland in
Google Scholar
PubMed
Search for other papers by S. J. Ratter in
Google Scholar
PubMed
Search for other papers by G. L. Bourne in
Google Scholar
PubMed
Search for other papers by L. H. Rees in
Google Scholar
PubMed
ABSTRACT
Corticotrophin releasing factor-like immunoreactivity (CRF-LI) and bioactivity, and arginine vasopressinlike immunoreactivity (AVP-LI) have been measured in extracts of human fetal and adult hypothalamic tissue and their development with the gestational age of the fetuses (12–27 weeks) studied. CRF-LI was measured by a radioimmunoassay developed for ovine corticotrophin-releasing factor (oCRF-41). Corticotrophin-releasing factor bioactivity was measured in a rat isolated anterior pituitary cell perfusion system. CRF-LI and bioactivity and AVP-LI were all detectable in fetal hypothalamic extracts from 12 to 13 weeks of gestational age. CRF-LI was also present in human fetal pituitary glands from 12 weeks of gestational age. The concentration of CRF-LI in the fetal hypothalamic extracts (9·2±11·4 ng/g, mean ± s.e.m., n = 33) showed no significant correlation with the gestational age of the fetuses. However the concentration of AVP-LI (25·0–36·8 ng/g, n = 17) did show a positive correlation (r = 0·508, P<0·05) with gestational age, as did the concentration of CRF bioactivity (471·3–556·3 ng ACTH released/g tissue, n = 13, r = 0·725, P < 0·01).
The CRF bioactivity of all fetal hypothalamic extracts was potentiated by the addition of synthetic human (h)AVP, but the bioactivity of the adult hypothalamic extracts was not, presumably because of the higher levels of AVP-LI already present in the adult extracts. Pretreatment of tissue extracts with antisera to oCRF-41 and/or hAVP reduced the CRF bioactivity of all hypothalamic extracts. Sephadex chromatography of fractions which co-eluted with synthetic oCRF-41 or hAVP contained CRF bioactivity and this bioactivity was potentiated when synthetic hAVP or oCRF-41, respectively, were added to the fractions. However, a larger molecular weight form of CRF-LI (8000–10 000 daltons), which was observed only in fetuses of 20 weeks of gestational age or less, did not contain any significant CRF bioactivity.
J. Endocr. (1986) 108, 171–180
Search for other papers by J. Ibanez-Santos in
Google Scholar
PubMed
Search for other papers by S. Tsagarakis in
Google Scholar
PubMed
Search for other papers by L. H. Rees in
Google Scholar
PubMed
Search for other papers by G. M. Besser in
Google Scholar
PubMed
Search for other papers by A. Grossman in
Google Scholar
PubMed
ABSTRACT
Atrial natriuretic peptide, ANP(99–126), is derived from cardiac atrial tissue and has potent effects on salt and water homeostasis, including the inhibition of aldosterone and vasopressin release. Recent studies have also suggested that it may suppress the pituitary-adrenal axis. In addition, N-truncated forms of ANP, such as ANP(103–126), have been identified within the central nervous system, with a prominent hypothalamic localization in the paraventricular nucleus. We have therefore investigated whether ANP(99–126) and ANP(103–126) are able to modulate the release of the principal ACTH-releasing factor, corticotrophin-releasing factor-41 (CRF-41), from the rat hypothalamus in vitro.
The static incubation system has been previously described in detail. Male Wistar rats were decapitated between 09.00 and 09.30 h, their hypothalami rapidly removed, and four half-hypothalami incubated for 20-min intervals following a period of stabilization. The effect of the ANP peptides on the basal (B) and KCl (28 mmol/l)-stimulated (S) release of immuno-reactive CRF-41 was studied by means of successive incubations in the absence (B1, SI) and presence (B2, S2) of the peptides. The ratios B2: B1 and S2: S1 were compared with parallel control incubations by ANOVA.
Neither form of ANP had any effect on the basal release of CRF-41. ANP(99–126) caused a dose-dependent inhibition of CRF-41 release in the concentration range 1–100 nmol (P < 0·01). ANP(103–126) also suppressed the release of CRF-41 in the concentration range 100 pmol/l–100 nmol/l (P < 0·01), with a minimum S2:S1 ratio at 10 nmol/l, and a decrease in effect at 100 nmol/l. Finally, the stimulation of CRF-41 release induced by noradrenaline (10 nmol/l and 1 μmol/l) was non-competitively antagonized by 100 nmol ANP(99–126)/l and 10 nmol ANP(103–126)/l.
It was concluded that ANP may be an important regulator of the pituitary-adrenal axis by interaction with CRF-41. As there are data indicating that ANP may also directly inhibit the pituitary corticotroph, it would appear that central ANP is intimately involved in pituitary-adrenal function.
Journal of Endocrinology (1990) 126, 223–228
